306 related articles for article (PubMed ID: 34571875)
1. Phosphorylation-Mediated Molecular Pathway Changes in Human Pituitary Neuroendocrine Tumors Identified by Quantitative Phosphoproteomics.
Li J; Wen S; Li B; Li N; Zhan X
Cells; 2021 Aug; 10(9):. PubMed ID: 34571875
[TBL] [Abstract][Full Text] [Related]
2. Quantitative Acetylomics Revealed Acetylation-Mediated Molecular Pathway Network Changes in Human Nonfunctional Pituitary Neuroendocrine Tumors.
Wen S; Li J; Yang J; Li B; Li N; Zhan X
Front Endocrinol (Lausanne); 2021; 12():753606. PubMed ID: 34712204
[TBL] [Abstract][Full Text] [Related]
3. Quantitative phosphoproteomics reveals molecular pathway network alterations in human early-stage primary hepatic carcinomas: potential for 3P medical approach.
Zhang Y; Li N; Yang L; Jia W; Li Z; Shao Q; Zhan X
EPMA J; 2023 Sep; 14(3):477-502. PubMed ID: 37605650
[TBL] [Abstract][Full Text] [Related]
4. Integration of quantitative phosphoproteomics and transcriptomics revealed phosphorylation-mediated molecular events as useful tools for a potential patient stratification and personalized treatment of human nonfunctional pituitary adenomas.
Liu D; Li J; Li N; Lu M; Wen S; Zhan X
EPMA J; 2020 Sep; 11(3):419-467. PubMed ID: 32849927
[TBL] [Abstract][Full Text] [Related]
5. Phosphorylation of β-catenin at Serine552 correlates with invasion and recurrence of non-functioning pituitary neuroendocrine tumours.
Rai A; Yelamanchi SD; Radotra BD; Gupta SK; Mukherjee KK; Tripathi M; Chhabra R; Ahuja CK; Kumar N; Pandey A; Korbonits M; Dutta P; Gaston-Massuet C
Acta Neuropathol Commun; 2022 Sep; 10(1):138. PubMed ID: 36114575
[TBL] [Abstract][Full Text] [Related]
6. SDF-1α/MicroRNA-134 Axis Regulates Nonfunctioning Pituitary Neuroendocrine Tumor Growth
Wang X; Fang Y; Zhou Y; Guo X; Xu K; Li C; Zhang J; Hong Y
Front Endocrinol (Lausanne); 2020; 11():566761. PubMed ID: 33362712
[TBL] [Abstract][Full Text] [Related]
7. Differential expression levels of β-catenin are associated with invasive behavior of both functional and non-functional pituitary neuroendocrine tumor (PitNET).
Taghavi SF; Ghorbani M; Panahi M; Nazem S; Karimi M; Salimi V; Tavakoli-Yaraki M
Mol Biol Rep; 2023 Aug; 50(8):6425-6434. PubMed ID: 37326745
[TBL] [Abstract][Full Text] [Related]
8. The expression of neural cell adhesion molecule and the microenvironment of pituitary neuroendocrine tumours.
Marques P; Barry S; Carlsen E; Collier D; Ronaldson A; Grieve J; Dorward N; Mendoza N; Nair R; Muquit S; Grossman AB; Korbonits M
J Neuroendocrinol; 2021 Dec; 33(12):e13052. PubMed ID: 34708902
[TBL] [Abstract][Full Text] [Related]
9. Lower
Tjörnstrand A; Casar-Borota O; Heurling K; Schöll M; Gjertsson P; Himmelman J; Itsenko O; Ragnarsson O; Filipsson Nyström H
Clin Endocrinol (Oxf); 2020 Mar; 92(3):222-231. PubMed ID: 31868239
[TBL] [Abstract][Full Text] [Related]
10. Phosphorylation-mediated PI3K-Art signalling pathway as a therapeutic mechanism in the hydrogen-induced alleviation of brain injury in septic mice.
Bai Y; Li L; Dong B; Ma W; Chen H; Yu Y
J Cell Mol Med; 2022 Nov; 26(22):5713-5727. PubMed ID: 36308410
[TBL] [Abstract][Full Text] [Related]
11. Identification of biomarkers associated with the invasion of nonfunctional pituitary neuroendocrine tumors based on the immune microenvironment.
Wu J; Guo J; Fang Q; Liu Y; Li C; Xie W; Zhang Y
Front Endocrinol (Lausanne); 2023; 14():1131693. PubMed ID: 37522128
[TBL] [Abstract][Full Text] [Related]
12. DRD2 Agonist Cabergoline Abolished the Escape Mechanism Induced by mTOR Inhibitor Everolimus in Tumoral Pituitary Cells.
Mangili F; Esposito E; Treppiedi D; Catalano R; Marra G; Di Muro G; Barbieri AM; Locatelli M; Lania AG; Mangone A; Spada A; Arosio M; Peverelli E; Mantovani G
Front Endocrinol (Lausanne); 2022; 13():867822. PubMed ID: 35721701
[TBL] [Abstract][Full Text] [Related]
13. Phosphoproteome profiling revealed abnormally phosphorylated AMPK and ATF2 involved in glucose metabolism and tumorigenesis of GH-PAs.
Zhao S; Feng J; Li C; Gao H; Lv P; Li J; Liu Q; He Y; Wang H; Gong L; Li D; Zhang Y
J Endocrinol Invest; 2019 Feb; 42(2):137-148. PubMed ID: 29691806
[TBL] [Abstract][Full Text] [Related]
14. Chemokines modulate the tumour microenvironment in pituitary neuroendocrine tumours.
Marques P; Barry S; Carlsen E; Collier D; Ronaldson A; Awad S; Dorward N; Grieve J; Mendoza N; Muquit S; Grossman AB; Balkwill F; Korbonits M
Acta Neuropathol Commun; 2019 Nov; 7(1):172. PubMed ID: 31703742
[TBL] [Abstract][Full Text] [Related]
15. Beta-Arrestin 2 Is Required for Dopamine Receptor Type 2 Inhibitory Effects on AKT Phosphorylation and Cell Proliferation in Pituitary Tumors.
Mangili F; Giardino E; Treppiedi D; Barbieri AM; Catalano R; Locatelli M; Lania AG; Spada A; Arosio M; Mantovani G; Peverelli E
Neuroendocrinology; 2021; 111(6):568-579. PubMed ID: 32512568
[TBL] [Abstract][Full Text] [Related]
16. Identification of cholesterol metabolism-related subtypes in nonfunctioning pituitary neuroendocrine tumors and analysis of immune infiltration.
Feng T; Hou P; Mu S; Fang Y; Li X; Li Z; Wang D; Chen L; Lu L; Lin K; Wang S
Lipids Health Dis; 2023 Aug; 22(1):127. PubMed ID: 37563740
[TBL] [Abstract][Full Text] [Related]
17. Progress in the Pathogenesis, Diagnosis, and Treatment of TSH-Secreting Pituitary Neuroendocrine Tumor.
Luo P; Zhang L; Yang L; An Z; Tan H
Front Endocrinol (Lausanne); 2020; 11():580264. PubMed ID: 33329389
[TBL] [Abstract][Full Text] [Related]
18. Transcriptomic analysis identifies a tumor subtype mRNA classifier for invasive non-functioning pituitary neuroendocrine tumor diagnostics.
Bao X; Wang G; Yu S; Sun J; He L; Zhao H; Ma Y; Wang F; Wang X; Wang R; Yu J
Theranostics; 2021; 11(1):132-146. PubMed ID: 33391466
[No Abstract] [Full Text] [Related]
19. Muti-omics integration analysis revealed molecular network alterations in human nonfunctional pituitary neuroendocrine tumors in the framework of 3P medicine.
Wen S; Li C; Zhan X
EPMA J; 2022 Mar; 13(1):9-37. PubMed ID: 35273657
[TBL] [Abstract][Full Text] [Related]
20. Pituitary Tumors: Genetic and Molecular Factors Underlying Pathogenesis and Clinical Behavior.
Spada A; Mantovani G; Lania AG; Treppiedi D; Mangili F; Catalano R; Carosi G; Sala E; Peverelli E
Neuroendocrinology; 2022; 112(1):15-33. PubMed ID: 33524974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
